PSA and alkaline phosphatase changes in the EORTC-1333 PEACE-3 study evaluating the addition of six cycles of radium 223 in metastatic castration-resistant prostate cancer (mCRPC) starting enzalutamide.
Bibliographic record
Abstract
5062 Background: The EORTC/UNICANCER/CTI/CUOG/LACOG Peace 3 showed that adding Ra233 to enzalutamide significantly improves investigator-assessed progression-free survival (PFS) and overall survival (OS) in mCRPC with bone metastases. We examined the effect of the combination on the decline in prostate-specific antigen (PSA) and alkaline phosphatase (ALP). Methods: From 11/2015 to 03/2023, 446 men with mCRPC and bone metastasis were randomized 1:1 to enzalutamide alone (ENZ) or combined with 6 cycles of Ra223 (ENZ-RAD). The PSA/ALP response rate is estimated at 6/12 months based on the drop from baseline in all PSA/ALP evaluable patients. For PSA, any decline ≥ 50 or 90% from baseline is considered a PSA response. For ALP, any decline of ≥30% from baseline is regarded as a response. Each response needed to be confirmed by a second evaluation at least three weeks later. Time to response is from treatment start until the first date a response was observed. ALP normalization is a decline to ≤ 115 U/L in patients with baseline ALP >115 U/L. Results: PSA: The baseline median (Q1-Q3) for ENZ-RAD was 24.0 (7.8-68.8) ng/dl, and 21.4 (8.0-57.6) ng/ml for ENZ. The median time (95%CI) to a PSA response > 50% in months (mo.) was 2.79 (2.56-3.02) in the ENZ-RAD arm and 2.76 (2.63-2.79) in the ENZ arm (HR (95%CI) 1.00 (0.80-1.24)). PSA response rates ≥50% at 6 and 12 months were 77.1% (145/188) and 76.8% (109/142) in the ENZ-RAD arm, compared to 69.9% (127/182) and 66.2% (88/133) in the ENZ arm. The median time (95%CI) to a PSA response ≥ 90% in mo. was 1.87 (1.44-2.53) in the ENZ-RAD arm and 7.44 (3.67-NE) in the ENZ arm (HR (95%CI 1.48 (1.13-1.93)). PSA response rates ≥90% at 6 and 12 mo. were 50.5% (95/188) and 54.9% (78/142) in the ENZ-RAD arm, compared to 34.1% (62/182) and 37.6% (50/133) in the ENZ arm. ALP: The baseline median (Q1-Q3) ALP in the ENZ-RAD arm was 106 (78-183) UI/L, and in the ENZ arm, 124.5 (85-216). In the ENZ/RAD and ENZ arms, 45.6% (99/217) and 54.4% (122/224) of patients had ALP ≥ 115 UI/L at baseline. The ENZ-RAD arm had a median time (95%CI) to ALP response > 30% of 2.40 (1.97-2.79) mo., while the ENZ arm had a median of 3.71 (2.83-5.49) mo. (HR (95%CI) 1.42 (1.13-1.80)). ALP >30% response rates at 6 and 12 mo. were 56.5% (108/191) and 50.0% (71/142) in ENZ-RAD and 50.8% (93/183) and 47.4% (63/133) in ENZ. The median (95%CI) time to ALP normalization in the ENZ-RAD arm is 1.97 (1.87-2.50) mo. and 4.47 (2.99-14.06) mo. In the ENZ arm(HR 1.42 (1.13-1.80)). At 6 and 12 mo., the ENZ-RAD arm ALP normalization rates were 76.2 (64/84) and 77.4 (41/53), while 50.5% (47/93) and 61.3% (38/62) in the ENZ arm. Conclusions: The addition of six cycles of RA 223 to enzalutamide in the PEACE-3 trial improves PSA response time and rates (≥90%), ALP reduction time (≥30%), and ALP normalization time and rates at 6 and 12 months. Clinical trial information: NCT02194842 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".